Neurocrine Biosciences Inc. (NASDAQ: NBIX) presented data showing functional improvements in patients with mild tardive dyskinesia treated with INGREZZA (valbenazine) capsules. The findings were presented at the American Psychiatric Association 2026 Annual Meeting in San Francisco.

The analysis examined 90 patients with mild tardive dyskinesia severity from a clinician survey. Prior to treatment, 90% of patients experienced functional impairment affecting emotional, social or physical functions. Following INGREZZA initiation, 96% of patients showed improvement in uncontrolled movements, with 86% improving within four weeks.

The survey included adult patients who initiated INGREZZA between January 1, 2024 and June 30, 2024, completed at least two months of treatment and had follow-up visits. Data from 128 clinicians caring for 315 patients with tardive dyskinesia was collected.

Among patients with functional status impairment, 96% showed improvement in overall functional status after treatment. More than 90% of patients experienced improvement across functional areas including speech, dexterity, social status, emotional status and activities of daily living. Additionally, 83% of all patients achieved improvement in independence, and 70% of employed or student patients experienced improved ability to work or attend school.

INGREZZA is approved by the U.S. Food and Drug Administration for treating tardive dyskinesia in adults and chorea associated with Huntington's disease. The drug is a selective vesicular monoamine transporter 2 inhibitor that reduces dopamine signaling to decrease uncontrollable movements.

Information in this article is based on a press release statement from Neurocrine Biosciences.